Salubris Biotherapeutic Raises $35 Million in Funding for Research and Development of Novel Biologic Therapeutics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Salubris Biotherapeutic's Funding and Research Updates

Key Highlights:

• Funding: Raised $35 million in funding, with additional commitment from Shenzhen Salubris.
• Research and Development: Funds will be used to expand research and development of clinical and pre-clinical programs.
• Biologic Therapeutics: Focus on developing novel biologic therapeutics for cardiovascular, oncology, and neurodegenerative diseases.

Salubris Biotherapeutic's Target Market

• Target Market: Patients suffering from cardiovascular, oncology, and neurodegenerative diseases.
• Healthcare Providers and Specialists: Cardiologists, oncologists, and neurologists seeking innovative biologic therapeutics for their patients.
• Pharmaceutical Companies and Research Institutions: Collaborations with pharmaceutical companies and research institutions for further development and clinical trials.

What Salubris Biotherapeutic Needs to Buy

• Research and Development Partnerships: Collaborations with biotech and pharmaceutical companies for joint research and development efforts.
• Clinical Trial Support: Services to support the planning, execution, and monitoring of clinical trials for their biologic therapeutics.
• Regulatory and Compliance Expertise: Consulting services to ensure compliance with regulatory requirements and navigate the approval process for their therapeutics.